Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.65 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.63 |
| ▸ | CTSD | P07339 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22990843 | 0.92 | BACE1 (0.71) | BACE1BACE2CTSD | |
| SCHEMBL17815408 | 0.92 | BACE1 (0.71) | BACE1BACE2CTSD | |
| SCHEMBL11917892 | 0.92 | BACE1 (0.73) | BACE1BACE2CTSD | |
| SCHEMBL11917950 | 0.92 | BACE1 (0.73) | BACE1BACE2CTSD | |
| SCHEMBL11917949 | 0.91 | BACE1 (0.72) | BACE1BACE2CTSD | |
| SCHEMBL14817193 | 0.90 | BACE1 (0.71) | BACE1BACE2CTSD | |
| SCHEMBL11917952 | 0.89 | BACE1 (0.75) | BACE1BACE2CTSD | |
| SCHEMBL11917958 | 0.89 | BACE1 (0.71) | BACE1BACE2CTSD | |
| SCHEMBL11917603 | 0.89 | BACE1 (0.82) | BACE1BACE2CTSD | |
| SCHEMBL17815402 | 0.89 | BACE1 (0.82) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202803-A1 | N-[3-(5-AMINO-3,3A,7,7A-TETRAHYDRO-1H-2,4-DIOXA-6-AZA-INDEN-7-YL)-PHENYL]-AMIDES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202803-A1 | N-[3-(5-AMINO-3,3A,7,7A-TETRAHYDRO-1H-2,4-DIOXA-6-AZA-INDEN-7-YL)-PHENYL]-AMIDES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, IAPP | BACE1 2/4885BACE2 1/4885CTSD 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.